- ISIN
- US45719W1062
- CUSIP
- 45719W106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 23, 2020
Highlights
- Market Cap
- $292.92M
- Enterprise Value
- $243.35M
- EPS (TTM)
- -$0.45
- Gross Profit (TTM)
- -$84.66K
- EBITDA (TTM)
- -$54.07M
- Year Range
- $1.33 - $2.26
- Target Price
- $4.00
- ROA (TTM)
- -29.40%
- ROE (TTM)
- -30.40%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IKT Performance Chart
Inhibikase Therapeutics, Inc. (IKT) is down 17.1% since the beginning of the year. At $2 per share, IKT is trading 24.8% below its 52-week high of $2. Investors who bought $1,000 worth of IKT shares 5 years ago would now be looking at an investment worth $53.
Loading charts...
Returns By Period
Inhibikase Therapeutics, Inc. (IKT) has returned -17.07% so far this year and -16.26% over the past 12 months.
Inhibikase Therapeutics, Inc.
- 1D
- -0.58%
- 1M
- -12.37%
- YTD
- -17.07%
- 6M
- 18.06%
- 1Y
- -16.26%
- 3Y*
- -26.42%
- 5Y*
- -44.48%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
IKT Monthly Returns History
Based on dividend-adjusted daily data since Dec 23, 2020, IKT's average daily return is -0.08%, while the average monthly return is -1.85%.
Historically, 40% of months were positive and 60% were negative. The best month was Jan 2024 with a return of +137.4%, while the worst month was Jun 2021 at -47.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, IKT closed higher 44% of trading days. The best single day was Jan 24, 2024 with a return of +37.7%, while the worst single day was Nov 7, 2022 at -40.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.83% | 36.67% | -18.05% | 12.50% | -7.41% | -2.86% | -17.07% | ||||||
| 2025 | -30.15% | 1.32% | -4.78% | 3.20% | -11.06% | -2.99% | -18.97% | 13.92% | -10.00% | -9.26% | 3.40% | 34.87% | -36.92% |
| 2024 | 137.44% | -28.37% | 0.00% | -31.94% | 25.17% | -34.24% | 16.53% | -0.71% | -7.14% | 94.62% | 15.42% | 11.30% | 155.91% |
| 2023 | 41.18% | 4.67% | -11.00% | -15.02% | 23.12% | -12.55% | -30.19% | -20.24% | -30.85% | -36.28% | 5.85% | 35.47% | -57.67% |
| 2022 | -4.76% | -24.29% | 39.62% | -27.03% | -15.20% | -18.91% | 14.45% | 12.91% | -5.17% | -15.14% | -21.63% | -17.38% | -65.99% |
| 2021 | -3.48% | 0.60% | -10.30% | -12.98% | 2.29% | -47.66% | -18.93% | 4.41% | -19.83% | 4.74% | 0.50% | -26.50% | -78.70% |
Benchmark Metrics
Inhibikase Therapeutics, Inc. has an annualized alpha of -29.33%, beta of 1.00, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since December 24, 2020.
- This stock participated in 143.67% of S&P 500 Index downside but only -80.56% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.33%
- Beta
- 1.00
- R²
- 0.03
- Upside Capture
- -80.56%
- Downside Capture
- 143.67%
Return for Risk
Risk / Return Rank
IKT ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Inhibikase Therapeutics, Inc. (IKT) and compare them to S&P 500 Index.
| IKT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.24 | 2.24 | -2.48 |
Sortino ratioReturn per unit of downside risk | 0.16 | 3.07 | -2.92 |
Omega ratioGain probability vs. loss probability | 1.02 | 1.41 | -0.39 |
Calmar ratioReturn relative to maximum drawdown | -0.56 | 2.93 | -3.49 |
Martin ratioReturn relative to average drawdown | -0.96 | 13.52 | -14.48 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Inhibikase Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Inhibikase Therapeutics, Inc. was 98.64%, occurring on Oct 9, 2023. The portfolio has not yet recovered.
The current Inhibikase Therapeutics, Inc. drawdown is 97.14%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -98.64%Oct 2023 | 2y 9mo | — | 5y 5moDec 2020 - now |
Drawdown Indicators
| IKT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.64% | -56.78% | -41.86% |
Max Drawdown (1Y)Largest decline over 1 year | -30.20% | -9.10% | -21.10% |
Max Drawdown (3Y)Largest decline over 3 years | -81.25% | -18.90% | -62.35% |
Max Drawdown (5Y)Largest decline over 5 years | -97.81% | -25.43% | -72.38% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.14% | -0.74% | -96.40% |
Average DrawdownAverage peak-to-trough decline | -88.34% | -10.72% | -77.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.30% | 1.97% | +16.33% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Inhibikase Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Inhibikase Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IKT in comparison with other companies in the Biotechnology industry. Currently, IKT has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IKT
Add Inhibikase Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IKT